Last reviewed · How we verify
Standard of Care for GVHD
Standard of Care for GVHD is a Mesenchymal stem cell therapy Small molecule drug developed by Mesoblast, Inc.. It is currently in Phase 3 development for Graft-versus-host disease.
Rexlemestrocel-L is a mesenchymal stem cell therapy that modulates the immune system to treat graft-versus-host disease.
Rexlemestrocel-L is a mesenchymal stem cell therapy that modulates the immune system to treat graft-versus-host disease. Used for Graft-versus-host disease.
At a glance
| Generic name | Standard of Care for GVHD |
|---|---|
| Sponsor | Mesoblast, Inc. |
| Drug class | Mesenchymal stem cell therapy |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
Rexlemestrocel-L works by promoting immune tolerance and reducing inflammation in the body. This is achieved through the administration of mesenchymal stem cells that have been engineered to express specific genes. The exact mechanisms by which these cells exert their effects are not fully understood, but they are thought to involve the modulation of various immune cell populations and the production of anti-inflammatory cytokines.
Approved indications
- Graft-versus-host disease
Common side effects
- Infusion-related reactions
- Fatigue
- Nausea
- Headache
- Diarrhea
Key clinical trials
- US Study of ECT-001-CB in Pediatric and Young Adult Patients With High-Risk Myeloid Malignancies (PHASE1, PHASE2)
- Haploidentical Transplant for People With Chronic Granulomatous Disease (CGD) Using Alemtuzumab, Busulfan and TBI With Post-Transplant Cyclophosphamide (EARLY_PHASE1)
- US Study of UM171-Expanded CB in Patients With High Risk Leukemia/Myelodysplasia (PHASE2)
- ECT-001 (UM171) Expanded Cord Blood Transplant to Treat High-risk Multiple Myeloma (PHASE1, PHASE2)
- A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation (PHASE2)
- Ocular Complications From Cancer Therapy - Patient Registry and Biobank
- Precision-T: A Randomized Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies (PHASE3)
- Biomarker-Guided Ruxolitinib for the Prevention of Chronic Graft Versus Host Disease After Allogeneic Hematopoietic Cell Transplantation (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Standard of Care for GVHD CI brief — competitive landscape report
- Standard of Care for GVHD updates RSS · CI watch RSS
- Mesoblast, Inc. portfolio CI
Frequently asked questions about Standard of Care for GVHD
What is Standard of Care for GVHD?
How does Standard of Care for GVHD work?
What is Standard of Care for GVHD used for?
Who makes Standard of Care for GVHD?
What drug class is Standard of Care for GVHD in?
What development phase is Standard of Care for GVHD in?
What are the side effects of Standard of Care for GVHD?
Related
- Drug class: All Mesenchymal stem cell therapy drugs
- Manufacturer: Mesoblast, Inc. — full pipeline
- Therapeutic area: All drugs in Immunology
- Indication: Drugs for Graft-versus-host disease
- Compare: Standard of Care for GVHD vs similar drugs
- Pricing: Standard of Care for GVHD cost, discount & access